Every year, ASCO stands as a defining moment in oncology research, and the 2026 meeting was no different. Our team has distilled the conference’s most significant market shifts and strategic imperatives, cutting through the volume to focus on what truly matters.
Below you’ll find bite-sized quotes from our specialists that provide a quick overview of the key developments addressed. For a comprehensive strategic analysis, download the full report.
Signals of change in frontline NSCLC
“Ivonescimab, I’m sure, has been on everyone’s watchlist, and this readout showed why. But how these results translate globally is still unclear, and that leaves a real planning question: how far do teams lean into this signal now versus waiting for global confirmation?” – Siobhan Davies
RAS gets its landmark moment
“The daraxonrasib data was one of those moments that just stays with you, showing how far the RAS field has come. What excites me looking ahead is the idea that pan-RAS and allele-specific approaches might come together to push outcomes further.” – Kate Goacher
ADCs: a call for payload diversification
“With so many topo-I ADCs in development, it’s getting harder to assume there’s an obvious place for your asset. It forces a more honest look at where you actually want to play, and whether you can genuinely improve on what’s already out there.” – Paula Coyle
HR+ mBC: embracing complexity
“There’s a lot of academic enthusiasm for tailored sequencing in HR-positive breast cancer, but most oncologists on the frontline just want clear direction, not more complexity. That’s a real question for brand teams: how do you actually deliver that clarity?” – Kirsty Hope
Our team is always up for a conversation on the latest clinical developments and what they mean for pharma strategy. If you’d like to discuss, we’d love to hear from you. And if you’d like the full debrief, download our report below.